



FINANCIAL TEAR SHEET

Corporate Profile

Apricus is committed to developing sexual health therapies in areas of high unmet needs. We have disciplined leadership focused on execution and are driving near-term shareholder value through regulatory approval, commercialization and partnering initiatives.

Stock Performance

APRI (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$0.40
Change (%)	▼ 0.01 (2.44%)
Volume	289,307
52 Week High	\$3.34
52 Week Low	\$0.25
Market Cap	\$9,376,432
Rolling EPS	-0.77
PE Ratio	0
Shares Outstanding	23,441,080

Data as of 07/20/18 3:59 p.m. ET



Recent Headlines

- 05/03/18
[Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results](#)
- 04/16/18
[Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA](#)
- 04/04/18
[Apricus Biosciences Announces Closing of \\$3.55 Million Public Offering](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
06/22/18	SC 13D/A
06/22/18	8-K
05/17/18	8-K
05/03/18	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)

© Apricus Biosciences, Inc.